source
- Microbiome startup raises $48M for immunotherapy and malnutrition treatmentsScientists trying to understand why cancer immunotherapy works so well for some patients and not others have found a potential answer in one cancer survivor's poop. A biotech startup has studied th…Endpoints · 2mo ago↗ source
- J&J's IBD combo fails Phase 2 studies, but will move into pivotal testingJohnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy's failure in two mid-stage trials. The company said that JNJ-4804, a combination of t…Endpoints · 2mo ago↗ source
- Madrigal extends MASH deal streak with Arrowhead drug that J&J didn't wantMadrigal Pharmaceuticals has made its fourth MASH deal in 10 months, further signaling its ambitions to be not just the first drugmaker for the fatty liver disease, but also the owner of the field'…